The combination treatment using ATO + ATRA overcomes the differentiation blockade in APL by efficiently degrading the PML–RARα fusion protein and by forming PML-nuclear bodies (Chen et al., 2011; Lo-Coco et al., 2013; de Thé, 2018). This evidence concerns the gene PML and acute promyelocytic leukemia.